FindTrial
Sign In

The effect of rofecoxib on colorectal liver metastases

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN29775286
Enrollment
Unknown
Registered
2001-07-01
Start date
1998-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer, liver metastases Cancer Malignant neoplasm of colon

Interventions

1. Rofecoxib 25 mg/day 2. Placebo

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age greater than or equal to 18 years 2. Either sex 3. Liver resection deemed clinically appropriate for management of metastatic Colorectal Cancer (CRC) liver disease 4. Duration between decision to perform liver resection and surgery greater than 2 weeks 5. Ability to give written informed consent 6. Telephone at home

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026